These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 34974337)

  • 1. Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate.
    Mohamed Amar IA; Huvelle S; Douez E; Letast S; Henrion S; Viaud-Massuard MC; Aubrey N; Allard-Vannier E; Joubert N; Denevault-Sabourin C
    Eur J Med Chem; 2022 Feb; 229():114063. PubMed ID: 34974337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency.
    Dovgan I; Ehkirch A; Lehot V; Kuhn I; Koniev O; Kolodych S; Hentz A; Ripoll M; Ursuegui S; Nothisen M; Cianférani S; Wagner A
    Sci Rep; 2020 May; 10(1):7691. PubMed ID: 32376903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC).
    Nunes JP; Morais M; Vassileva V; Robinson E; Rajkumar VS; Smith ME; Pedley RB; Caddick S; Baker JR; Chudasama V
    Chem Commun (Camb); 2015 Jul; 51(53):10624-7. PubMed ID: 26051118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
    Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
    MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
    Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA
    Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of attachment site on stability of cleavable antibody drug conjugates.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenyldivinylsulfonamides for the construction of antibody-drug conjugates with controlled four payloads.
    Wei D; Jiang Y; Mao Y; Xu Z; Chen J; Gao X; Li J; Jiang B; Chen H
    Bioorg Chem; 2023 May; 134():106463. PubMed ID: 36924655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.
    Dal Corso A; Cazzamalli S; Gébleux R; Mattarella M; Neri D
    Bioconjug Chem; 2017 Jul; 28(7):1826-1833. PubMed ID: 28662334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
    Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N
    Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates.
    Huang R; Sheng Y; Wei D; Lu W; Xu Z; Chen H; Jiang B
    Bioorg Med Chem; 2020 Dec; 28(23):115793. PubMed ID: 33039798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
    Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
    Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line.
    Abdollahpour-Alitappeh M; Hashemi Karouei SM; Lotfinia M; Amanzadeh A; Habibi-Anbouhi M
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1-8. PubMed ID: 29523024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.
    Kolodych S; Michel C; Delacroix S; Koniev O; Ehkirch A; Eberova J; Cianférani S; Renoux B; Krezel W; Poinot P; Muller CD; Papot S; Wagner A
    Eur J Med Chem; 2017 Dec; 142():376-382. PubMed ID: 28818506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
    Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.